Keywords: Targacept. Cornerstone, Nicotine receptor, Inflammatory diseases, License
Targacept licenses nicotine receptor from Cornerstone for up to $75 million
Article | 04 August 2010
US firm Targacept has acquired worldwide rights to fellow USA-based Cornerstone Therapeutics’ nicotinic-receptor based patents and library of preclinical compounds ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
